Skip to main content

Table 2 Change of parameters after 12-week exenatide treatment in T2DM patients (n = 38)

From: The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study

ParametersPre-treatmentExe-treatmentP-value*
Weight, kg93.1 ± 17.186.2 ± 18.1<0.01
BMI, kg/m231.2(28.5–35.1)29.4(25.3–32.8)<0.01
TC, mmol/L5.05 ± 1.114.30 ± 0.92<0.01
HDL-C, mmol/L1.15 ± 0.461.14 ± 0.280.899
LDL-C, mmol/L2.92 ± 0.802.57 ± 0.83<0.01
TG, mmol/L2.16(1.26–4.21)1.37(0.94–2.95)<0.01
FTBAs, μmol/L3.84 ± 2.063.06 ± 1.27<0.01
HbA1c, %9.69 ± 2.026.51 ± 0.94<0.01
FPG, mmol/L9.19 ± 3.466.42 ± 1.08<0.01
FINS, mU/L9.44 ± 5.2211.02 ± 4.530.128
C-peptide, mU/L2.83 ± 1.033.11 ± 0.840.112
HOMA-B38.81(20.13–61.98)79.60(48.47–106.09)<0.01
  1. Data presented as means ± SD or medians (interquartile range)
  2. P-value* were calculated by paired sample t test, exe-treatment vs. pre-treatment